Comparative Pharmacology
Head-to-head clinical analysis: K 10 versus K 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 10 versus K 8.
K+10 vs K+8
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
None Documented
None Documented
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Category C
Category C
Potassium Supplement
Potassium Supplement